Combined detection of Her2/neu gene amplification and protein overexpression in effusions from patients with breast and ovarian cancer

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 9, 2010, Pages 1389-1400

  Schlüter, Birgitta ^a   Gerhards, Roswitha ^a   Strumberg, Dirk ^a   Voigtmann, Rudolf ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Breast cancer; Effusions; FISH; Her2 neu gene amplification; Her2 neu overexpression; IHC; Ovarian cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERBB2 PROTEIN, HUMAN;

ARTICLE; ASCITES; BREAST CANCER; CHROMOSOME 17; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; OVARY CANCER; PLEURA EFFUSION; POLYPLOIDY; PRIORITY JOURNAL; SCORING SYSTEM; ASCITES FLUID; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; OVARY TUMOR;

ASCITIC FLUID; BREAST NEOPLASMS; CHROMOSOMES, HUMAN, PAIR 17; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; OVARIAN NEOPLASMS; PLEURAL EFFUSION; RECEPTOR, ERBB-2;

EID: 77955479419     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0790-2     Document Type: Article

References (58)

1. G Acs L Wang PN Raghunath MA Salscheider PJ Zhang 2003 Role of different immunostaining patterns in Herceptest interpretation and criteria for gene amplification as determined by fluorescence in situ hybridization Appl Immunohistochem Mol Morphol 11 3 222 229 1:CAS:528:DC%2BD3sXntFSnsbc%3D 12966348
2. R Ainsworth JM Bartlett JJ going EA Mallon A Forsyth J Richmond W Angerson A Watters B Dunne 2005 IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than Herceptest in breast carcinoma J Clin Pathol 58 10 1086 1090 10.1136/jcp.2004.021576 1:CAS:528:DC%2BD2MXhtFKjtbfK 16189156
3. L Bermont MP Algros MH Baron GL Adessi 2000 Relevance of p185 Her-2/neu oncoprotein quantification in human primary breast carcinoma Breast Cancer Res Treat 63 163 169 10.1023/A:1006420615690 1:CAS:528:DC%2BD3cXos1yjtrw%3D 11097092
4. M Bilous C Ades J Armes, et al. 2003 Predicting the HER2 status of breast cancer from basic histopathology data, an analysis of 1500 breast cancers as part of the HER 2000 international study Breast 12 92 98 10.1016/S0960-9776(02) 00273-4 1:STN:280:DC%2BD3srnvVyktw%3D%3D 14659337
5. AM Bofin, et al. 2003 TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas Cytopathology 14 314 319 10.1046/j.0956-5507. 2003.00088.x 1:STN:280:DC%2BD3sngtVahsA%3D%3D 14632728
6. O Brison 1993 Gene amplification and tumour progression Biochim Biophys Acta 1155 25 41 1:CAS:528:DyaK3sXlslynsb0%3D 8504129
7. C Ceccarelli D Santini M Gamberoni 1999 Immunohistochemical expression of internal and external ErbB2 domains in invasive breast cancer Breast Cancer Res Treat 58 107 114 10.1023/A:1006357524171 1:STN:280:DC%2BD3c7jsleguw%3D%3D 10674874
8. CH Chang JH Chiu LM Tseng CH Chang TM Chien CW Wu WY Lui 2006 Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells Eur J Clin Invest 36 8 588 596 10.1111/j.1365-2362.2006.01676.x 1:CAS:528: DC%2BD28XpvVeltbg%3D 16893382
9. E Downs-Kelly BJ Yoder M Stoler RR Tubbs M Skacel T Grogan P Roche D Hicks 2005 The influence of polysomy 17 on Her2 gene and protein expression in adenocarcinoma of the breast Am J Surg Pathol 29 9 1221 1227 10.1097/01.pas.0000165528.78945.95 16096413
10. AM Ervens M Otte C Egen K Pantel 2001 Her-2/neu FISH on cytokeratin-positive cells in bone marrow from breast cancer patients: establishment of the method (3rd international symposium on minimal residual cancer, 16-18-Feb 2001, Hamburg, Germany) Eur J Clin Investig 36 8 588 596
11. PA Fetsch A Abati 2007 The effect of antibody clone and pre-treatment method on the results of HER2 immunostaining in cytologic samples of metastatic breast cancer: a query and a review of the literature Diagn Cytopathol 35 6 319 328 10.1002/dc.20638 17497656
12. A Glazyrin X Shen V Blanc JF Eliason 2007 Direct detection of herceptin/trastuzumab binding on breast tissue sections J Histochem Cytochem 55 1 25 33 10.1369/jhc.6A7017.2006 1:CAS:528:DC%2BD2sXjvVCq 16957165
13. BA Gusterson LG Machin WJ Gullick, et al. 1988 Immunohistochemical distribution of c-erb-B2 in infiltrating and in situ breast cancer Int J Cancer 42 842 845 1:STN:280:DyaL1M%2FltlGhsA%3D%3D 2903851
14. L Hammock M Lewis 2006 Strong Her-2neu protein overexpression by immunohistochemistry often does not predict oncogene amplification by fluorescence in situ hybridization Hum Pathol 34 10 1043 1047 10.1053/S0046-8177(03)00409-X
15. LN Harris L Yang V Liotecheva S Pauli JD Iglehart OM Colvin TS Hsieh 2001 Induction of topoisomerase II activity after erbB2 activation is associated with a different response to breast cancer chemotherapy Clin Cancer Res 7 1497 1504 1:CAS:528:DC%2BD3MXltV2iu7w%3D 11410482
16. M Hofmann O Stoss T Gaiser H Kneitz P Heinmöller T Gutjahr M Kaufmann T Henkel J Rüschoff 2008 Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy J Clin Pathol 62 1 89 94 10.1136/jcp.2008.060046
17. TL Hung FF Chen JM Liu 2003 Clinical evaluation of Her2/neu protein in malignant pleural effusion-associated lung adenocarcinoma and as tumor marker in pleural effusion diagnosis Clin Cancer Res 9 2605 2612 1:CAS:528: DC%2BD3sXlt1yrsrg%3D 12855637
18. J Isola M Tanner 2004 Chromogenic in situ hybridization in tumour pathology Methods Mol Med 97 133 144 1:CAS:528:DC%2BD2cXjslGktro%3D 15064490
19. K Khosrotehrani H Stroh DW Bianchi 2003 Combined FISH and immunolabeling on paraffin-embedded tissue sections for the study of microchimirism Biotechniques 34 242 244 1:CAS:528:DC%2BD3sXhtlCitL0%3D 12613243
20. RE Kibbelaar H van Kamp EJ Dreef JC de Groot-Swings JC Kluin-Nelemans GC Beverstock WE Fibbe PhM Kluin 1992 Combined immunophenotyping and DNA in Situ hybridization to study lineage involvement in patients with myelodysplatic syndromes Blood 79 1823 1828 1:STN:280:DyaK383hs1Sqtg%3D%3D 1558974
21. P Lal PA Salazar M Ladanyi B Chen 2003 Impact of polysomy 17 on HER-2/neu immunohistochemistry in breast carcinoma without HER-2/neu gene amplification J Mol Diagn 5 153 159
22. PJ Lamy Fina F Nanni F Bibeau S Romain C Dussert F Penault Llorca J Grenier LH Quafik PM Martin 2006 Reliability and discriminant validity of HER2 gene quantification and chromosome 17 aneusomy analysis by real-time PCR in primary breast cancer Int J Biol Markers 21 1 20 29 1:CAS:528: DC%2BD28XlsVeltbo%3D 16711510
23. TE Li-Ning 2005 Role of chromogenic in situ hybridization in the evaluation of HER2 status in breast carcinoma: comparison with immunohistochemistry and FISH Int J Surg Pathol 13 4 343 351 10.1177/106689690501300406
24. Ch Lottner St Schwarz S Diermeier A Hartmann R Knuechel F Hofstaedter G Brockhoff 2005 Simultaneous detection of Her2/neu gene amplification and protein overexpression in paraffin-embedded breast cancer J Pathol 205 5 577 584 10.1002/path.1742 1:CAS:528:DC%2BD2MXjvVajtb8%3D 15732132
25. Y Ma L Lespagnard V Durbecq M Paesmans C Desmedt M Gomez-caldon I Veys F Cardoso C Sotiriou A Di Leo M Piccart D Larismont 2005 Polysomy 17 HER-2/neu status elaboration in breast cancer: effect on daily practice Clin Cancer Res 11 12 4393 4399 10.1158/1078-0432.CCR-04-2256 1:CAS:528:DC%2BD2MXltFeksrw%3D 15958623
26. JI Martin-Subero I Chudoba L Harder Gesk St W Grote FJ Novo MJ Calasanz R Siebert 2002 Multicolour-fiction expanding the possibilities of combined morphologic, immunophenotypic and genetic single cell analyses Am J Pathol 161 413 420 1:CAS:528:DC%2BD38XntFektbs%3D 12163366
27. AK Meeker, et al. 2002 Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridisation and immunostaining Am J Pathol 160 1259 1268 1:CAS:528:DC%2BD38XjsFGjtr4%3D 11943711
28. R Ni AM Mulligan C Have FP Omalley 2007 PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for assessment of ErbB2 (Her2/neu) status in breast cancer Appl Immunohistochem Mol Morphol 15 3 316 324 10.1097/01.pai.0000213138.01536.2e 1:CAS:528:DC%2BD2sXhtFGqu7fM 17721278
29. PC Nowell JD Rowley AG Knudson 1998 Cancer genetics, cytogenetics- defining the enemy within Nat Med 4 1107 1111 10.1038/2598 1:CAS:528: DyaK1cXms1Ggsbo%3D 9771733
30. N Pandis Y Jin L Gorunova C Pterson G Bardi I Idvall B Johansson C Ingvar N Mandahl F Mitelman 1995 Chromosome analysis of 97 primary breast carcinomas: identification of eight karyotype subgroups Genes Chrom Cancer 12 173 185 10.1002/gcc.2870120304 1:CAS:528:DyaK2MXktlyltLo%3D 7536456
31. G Pauletti S Dandekar HM Rong, et al. 2000 Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence In situ hybridization and immunohistochemistry J Clin Oncol 18 3651 3664 1:CAS:528:DC%2BD3cXot1antrg%3D 11054438
32. ZP Pavelic L Pavelic EE Lower 1992 C-myc, c-erbB2 and Ki-67 expression in normal breast tissue and in invasive and non-invasive breast carcinoma Cancer Res 52 2597 2606 1:CAS:528:DyaK38XktVGhsb8%3D 1348967
33. EA Perez 1999 Her-2 as a prognostic, predictive and therapeutic target in breast cancer Cancer Control 6 233 240 10758552
34. EA Perez PC Roche RB Jenkins CA Reynolds KC Halling JN Ingle LE Wold 2002 Her2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization Mayo Clinic Proc 77 148 154 10.4065/77.2.148
35. NC Popescu CR King MH Kraus 1989 Localization of the human erb-B2 gene on normal and rearranged chromosome 17 to bands q12-21.32 Genomics 4 362 366 10.1016/0888-7543(89)90343-1 1:CAS:528:DyaL1MXit1Knsb8%3D 2565881
36. MF Press MC Pike VR Chazin G Hung JA Udove M Markovicz J Danyluk W Godolphin M Sliwkowski R Akita, et al. 1993 Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease Cancer Res 53 4960 4970 1:CAS:528:DyaK2cXlvFCm 8104689
37. RL Ridolfi MR Jamehdor JM Arber 2000 Her2/neu testing in breast carcinoma: a combined immunohistochemical and fluorescence in situ hybridization approach Mod Pathol 13 8 866 873 10.1038/modpathol.3880154 1:STN:280: DC%2BD3M%2Fkt1Kltw%3D%3D 10955453
38. JS Ross JA Fletcher JB Kenneth, et al. 2004 Targeted therapy in breast cancer: the HER-2 neu gene and protein Mol Cell Proteomics 3 379 398 10.1074/mcp.R400001-MCP200 1:CAS:528:DC%2BD2cXivFCksLs%3D 14762215
39. T Sauer K Beraki PW Jebsen E Ormerod O Naess 1998 Numerical aberrations of chromosome 17 in interphase cell nuclei of breast carcinoma cells: lack of correlation with abnormal expression of P53, neu and nm23 protein APMIS 106 921 927 10.1111/j.1699-0463.1998.tb00240.x 1:STN:280:DyaK1M%2FkvFCgug%3D%3D 9833692
40. T Sauer G Wiedswang G Boudjiema H Christensen R Karesen 2003 Assesment of HER2/neu overexpression and/or gene amplification in breast carcinomas: should in situ hybridization be method of choice APMIS 111 444 450 10.1034/j.1600-0463. 2003.t01-1-1110210.x 1:CAS:528:DC%2BD3sXkt1KmsLc%3D 12752225
41. Schlueter B, Gerhards R, Voigtmann R (2002) Examination of tumour cells in exudate samples from patients with breast cancer and ovarian cancer. Comparison of Her2/neu status and protein expression by simultaneously performed IF and FISH. Abstract. Deutscher Krebskongress, Berlin
42. DJ Slamon GM Clark Levin WJ WongSG A Ullrich WL McGuire 1987 Human breast cancer: correlation of relapse and survival with amplification of the ERBB2 oncogene Science 235 177 181 10.1126/science.3798106 1:CAS:528: DyaL2sXhtVSht7s%3D 3798106
43. DJ Slamon W Godolphin B La Jones JA Holt SG Wang DE Keith 1989 Studies of the ERBB proto-oncogene in human breast and ovarian cancer Science 244 707 712 10.1126/science.2470152 1:STN:280:DyaL1M3kt1Wntg%3D%3D 2470152
44. DJ Slamon B Leyland-Jones S Shaks H Fuchs V Paton A Bajamonde T Fleming W Eiermann J Wolter M Pegram J Baselga L Norton 2001 Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2 N Engl J Med 344 783 792 10.1056/NEJM200103153441101 1:CAS:528: DC%2BD3MXisVGktrc%3D 11248153
45. Mc Cormick St TJ Lillemoe J Beneke J Schrauth J Reinartz 2002 Her2 Assessment by immunohistochemical analysis and fluorescence in situ hybridization Am J Clin Pathol 117 935 943 10.1309/3643-F955-7Q6B-EWWL
46. A Streit CD Stern 2001 Combined whole-mount in- situ-hybridisation and immunostaining in avian embryos Methods 23 339 344 10.1006/meth.2000.1146 1:CAS:528:DC%2BD3MXivVKnsrg%3D 11316435
47. H Tsuda 2006 Her-2 (c-erbB-2) test update: present status and problems Breast Cancer 13 236 248 10.2325/jbcs.13.236 16929116
48. F Tsukamoto Y Miyoshi Ch Egawa T Kasugai S Takami J Inazawa S Noguchi 2001 Clinicopathologic analysis of breast carcinoma with chromosomal aneusomy detected by fluorescence in situ hybridization Cancer 93 165 170 10.1002/cncr.9024 1:STN:280:DC%2BD3M3hvV2ksw%3D%3D 11309784
49. M Van de Vijer JL Petersen WJ Moois, et al. 1988 Neu protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer N Engl J Med 319 1239 1245
50. D Varshney YY Zhou SA Geller R Alsabeth 2004 Determination of Her2 status and chromosome 17 polysomy in breast carinomas comparing hercepttest and PathVysion FISH assay Am J Clin Pathol 121 70 77 10.1309/FUQH92B039025LHG 1:CAS:528:DC%2BD2cXht1ems7c%3D 14750243
51. A Vincent-Salomon G MacGrogan J Couturier 2003 Calibration of immunohistochemistry for assessment of Her2 in breast cancer: results of French multi-center GEFPICS study Histopathology 42 337 347 10.1046/j.1365-2559.2003. 01598.x 1:STN:280:DC%2BD3s7nvFyisg%3D%3D 12653945
52. Vogel CL, Cobleigh M, Tripathy R, Murphy M, Stewart SJ (2001) Superior outcomes with Herceptin (trastuzumab) (H) fluorescence in situ hybridisation (FISH)-selected patients. Proc Am Soc Clin Oncol 20:22a, abstract 86
53. CL Vogel MA Cobleigh D Tripathy JC Gutheil LN Harris L Fehrenbacher DJ Slamon M Murphy M Press 2002 Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER-2- overexpressing metastatic breast cancer J Clin Oncol 20 719 726 10.1200/JCO.20.3.719 1:CAS:528:DC%2BD38XhsVGmt7o%3D 11821453
54. S Wang MH Saboorian EP Frenkel BB Haley MT Siddiqui S Gokaslan FH Wians L Hynan R Ashfaq 2002 Aneusomy 17 in breast cancer: its role in ERBB2 protein expression and implication for clinical assessment of ERBB2 status Mod Pathol 15 137 145 10.1038/modpathol.3880505 11850542
55. AD Watters JJ Going TG Cooke JM Bartlett 2003 Chromosome 17 aneusomy is associated with poor prognostic factors in invasive breast carcinoma Breast Cancer Res Treat 77 109 114 10.1023/A:1021399923825 1:CAS:528: DC%2BD38Xpt1Kqt7s%3D 12602909
56. K Weber-Matthiesen M Winkelmann A Müller Hermelink B Schlegelberger W Grote 1992 Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumour cells J Histochem Cytochem 40 171 175 1:STN:280:DyaK383gt1KntQ%3D%3D 1552161
57. AC Wolff ME Hammond JN Schwartz KL Hagerty DC Alfred 2007 American society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human epidermal growth factor receptor 2 testing in breast cancer Arch Pathol Lab Med 131 1 18 43 1:CAS:528:DC%2BD2sXhsVOmu74%3D 19548375
58. H Yamauchi V Stearns DF Hayes 2001 When is a tumour marker ready for prime time? A case study of c-erbB2 as a predictive factor in breast cancer J Clin Oncol 19 2334 2356 1:CAS:528:DC%2BD3MXjsFeqsrg%3D 11304787